New and future antibiotics in the treatment of acute respiratory tract infections At first sight it might be thought that there are too many antibiotics available and that the last thing one would want is yet more agents. Such a nihilistic approach, however, is both inaccurate and shortsighted. We live in a changing world and, as far as bacteria are concerned, very much a global village. The conservative prescribing habits of one group of clinicians may be influenced by clinical activities further afield -for example, the increased numbers of penicillin insensitive 
Macrolides
Macrolide antimicrobials such as azithromycin, clarithromycin, and dirithromycin are now available in certain countries. These compounds have been developed to overcome the internal rearrangement of the erythromycin molecule which occurs at low pH (as in the stomach) causing alteration to gut motility with consequent side effects. The main differences between erythromycin and these newcomers are the longer elimination half lives (and hence longer dosing intervals) and the somewhat lower incidence of side effects. There are no major differences in antimicrobial activities and cross resistance amongst the group is the rule. An interesting facet of these agents is the superior intracellular penetration of azithromycin and clarithromycin.1415 This implies that, not only are they effective against intracellular pathogens, but clarithromycin, at least, is effective in Mycobacterium aviumintracellulare infections where the therapeutic options are very limited. These new agents may well supplant erythromycin for the treatment of "atypical pneumonia" but the pressure to use them in more trivial infections of the upper airway should be resisted.
Beta-lactams
There have been lesser advances amongst the f-lactam antimicrobials. The injectable cephalosporins, cefpirome and cefepime, have modest pharmacokinetic advantages over some earlier agents and are generally more stable to the bacterial hydrolysing enzymes, the f-lactamases. They will find a role in the treatment of nosocomial pneumonia.
Wtse
Meropenem is a carbapenem like imipenem but, unlike its predecessor, the new compound does not require to be administered with an enzyme blocking agent. Undoubtedly meropenem will also be used to treat the seriously ill patient with a nosocomial pneumonia.
Oral cephalosporins are proliferating. They have more in common with each other than they have differences, tending to be more active, more stable to the P-lactamases, and more expensive than the earlier compounds, cephalexin and cefaclor, to which they have not, to my knowledge, been shown to be clinically superior other than in frequency of administration. Generally, those that are more active against Gram negative pathogens -for example, cefixime and ceftibuten -are less active against streptococci. Cefpodoxime appears to be a reasonable compromise but no paediatric formulation is yet available. Loracarbef is not strictly a cephalosporin (rather a carbacephem), is available in a number of countries (but not the UK), and is a modest advance on earlier agents. The problem in assessing the usefulness of any of these oral agents in chest infections in the community ( moniae, but they are also active against those strains which have become resistant to tetracycline. Perhaps there will be a renaissance in this group of agents if their toxicological and pharmacokinetic assessment is trouble-free.
In the rapidly changing world of bacterial pathogens another group of antimicrobial drugs to join the armamentarium would be welcome. 
